Key statistics
On Friday, Context Therapeutics Inc (CNTX:NAQ) closed at 2.26, -17.82% below its 52-week high of 2.75, set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.39 |
---|---|
High | 2.50 |
Low | 2.23 |
Bid | 1.88 |
Offer | 2.15 |
Previous close | 2.23 |
Average volume | 213.82k |
---|---|
Shares outstanding | 75.00m |
Free float | 72.91m |
P/E (TTM) | -- |
Market cap | 169.50m USD |
EPS (TTM) | -1.06 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
- Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
- Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
- Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
- Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
- Context Therapeutics Announces $100 Million Private Placement
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results
- Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
More ▼